Media Center

News Releases

KYTHERA Biopharmaceuticals Announces Two Data Presentations on Its Novel Fat Reduction Drug at ASPS Meeting
October 22, 2009

What: Presentation of Phase 2 Data on ATX-101, a First-in- Class, Novel, Injectable Drug For The Reduction of Localized Fat and New Data on Pharmacokinetics, Histology and MOA. When: “Hot Topics in Plastic Surgery” – 1:00 p.m. (PDT) Friday, Oct. 23, 2009 (Phase 2 Data) General Session – 8:00 am to 9:00 a.m. (PDT) Monday,…

KYTHERA Biopharmaceuticals Presents Positive Data From Two Phase 2 Studies with ATX-101 – Study Results Demonstrated Statistically Significant Reduction in Patients’ Unwanted Submental Fat
October 2, 2009

LOS ANGELES, Oct. 2 (Business Wire) – KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today presented detailed results from two double-blind Phase 2 studies, each designed to evaluate the safety and effectiveness of ATX-101, a first-in-class injectable drug for the reduction of small volumes of fat. Top-line results from these studies, which examined use of ATX-101 for reduction…

Kythera Biopharmaceuticals Presents Positive Data From Two Phase 2 Studies With ATX-101
October 2, 2009

Study results demonstrated statistically significant reduction in patients’ unwanted submental fat LOS ANGELES, Oct. 2 (Business Wire) – KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today presented detailed results from two double-blind Phase 2 studies, each designed to evaluate the safety and effectiveness of ATX-101, a first-in-class injectable drug for the reduction of small volumes of fat. Top-line…

MEDIA ADVISORY — KYTHERA Biopharmaceuticals Announces Presentation Of Phase 2 Data On Novel Fat Reduction Drug At ASDS Meeting
October 1, 2009

What: Presentation of Phase 2 Data on ATX-101, a First-in-Class, Novel, Injectable Drug For The Reduction of Localized Fat When: 11:00 a.m. (MST/PDT) Friday, Oct. 2, 2009 (2:00 p.m. Eastern, 1:00 p.m. Central) Where: The American Society for Dermatologic Surgery (ASDS) and American Society of Cosmetic Dermatology and Aesthetic Surgery (ASCDAS) Joint Annual Meeting, Phoenix,…

KYTHERA Biopharmaceuticals Announces Initiation Of First-In-Human Trial For ATX-104 — A Light-Activated Facial Contouring Agent
September 15, 2009

LOS ANGELES, September 15, 2009 – KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced that it has initiated a first-in-human, proof-of-concept study evaluating the safety, tolerability, persistence and histological effects of ATX-104, a light-activated facial contouring agent. “We are very excited to move ATX-104 into the clinic,” said Patricia Walker, MD, PhD, KYTHERA’s Chief Medical Officer. “In…

KYTHERA Biopharmaceuticals To Participate In The Private Company Forum At The 30th Annual Goldman Sachs Global Healthcare Conference
June 1, 2009

LOS ANGELES, June 1, 2009  – KYTHERA Biopharmaceuticals, Inc. (“Kythera”) announced today its participation in the private company forum at the 30th Annual Goldman Sachs Global Healthcare Conference on Monday, June 8, 2009 from 3:30 to 5:30 p.m. Eastern Time. This event marks KYTHERA’s third appearance at the Goldman Sachs Private Company Forum. The Company…

KYTHERA Biopharmaceuticals, Inc. Selected To Present At Insideventure’s Debut Investor Conference, March 25-26, Santa Barbara, CA
March 24, 2009

Los Angeles, CA – March 24, 2009 – KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced that Keith Leonard, President and CEO, will present at InsideVenture’s Debut Conference, March 25-26, 2009 in Santa Barbara, California. KYTHERA has been selected from over 170 nominations to be one of 50 top private companies showcased to long-term investors through presentations…

KYTHERA Biopharmaceuticals Secures Additional $10M – Financing Follows Positive Phase II Data In Two Clinical Trials
February 18, 2009

LOS ANGELES, FEB 18, 2009 – KYTHERA BIOPHARMACEUTICALS, Inc. (“KYTHERA”), a privately-held biotechnology company focused on developing and commercializing novel products in aesthetic dermatology, announced that its investors elected early to exercise their rights to invest an additional $10 million as part of a $40 million Series C financing. All existing investors participated, including Versant…

Los Angeles Venture Association 6th Annual Awards Dinner Honors Elevation Partners’ Ted Meisel, 7 Entrepreneurs
January 23, 2009

Los Angeles, CA. – January 22, 2009 – The Los Angeles Venture Association (LAVA) held its Sixth Annual Venture Awards Dinner Wednesday evening to honor Southern California’s best growth companies and to present the Lifetime Achievement Award in Entrepreneurism to Elevation Partners’ Ted Meisel. The awards dinner was attended by over 200 leaders in the…

KYTHERA Biopharmaceuticals Announces Positive Results from Two Phase 2 Studies with ATX-101 Demonstrating Reduction of Submental Fat
January 6, 2009

LOS ANGELES, January 6, 2009 – KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced that it has successfully completed two Phase 2 clinical studies demonstrating the efficacy, safety, and tolerability of its lead product candidate, ATX- 101, for the reduction of submental (‘under-the-chin’) fat. The two Phase 2, randomized, double-blind, placebo-controlled, dose-ranging studies enrolled a total of…